Denali Therapeutics Inc. - 8-K Filing
Denali Therapeutics Inc. filed to announce that its Phase 2b LUMA study evaluating BIIB122 (DNL151) in early-stage Parkinson’s disease did not meet primary or secondary endpoints. Based on these results, Denali and Biogen will discontinue development of BIIB122 for idiopathic Parkinson’s disease but will continue the Phase 2a BEACON study in LRRK2 variant carriers. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $DNLI